BTBD10

Across TCGA pan-cancer cohorts, BTBD10 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BTBD10 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BTBD10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTBD10 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

LUAD, LSCC, and GBM are the cancer types where BTBD10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.491	0.905	<.001	36	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.566	.007	24	view →
GBM	OS	Quartile	All	0.256	0.568	.004	10	view →
UCEC	OS	Median	All	1.000	0.913	.025	6	view →
CCRCC	DFS	Median	All	0.306	1.000	.036	2	view →
HNSC	DFS	Tertile	II,III,IV	0.815	0.604	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BTBD10–LUAD (DFS)

Open the LUAD breakdown →